Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan

Devendra, Devasenan; Gohel, B; Bravis, Vassiliki; Hui, Elaine; Salih, Saba Ibrahim; Mehar, Salma; Hassanein, Mohammed

doi:10.1111/j.1742-1241.2009.02171.x

Cited by 75 publications

(90 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, because of the MTD requirement, for patients randomized to sulphonylurea, the pre‐trial sulphonylurea was to be kept stable until Ramadan. The dose of sulphonylureas in this trial was, however, consistent with or higher than doses used in other Ramadan trials, as well as in clinical practice 9, 10, 11, 31, 32, 33, 34. Generally, for sulphonylureas administered at higher than half the maximum approved dose, the glucose‐lowering effect levels off as the dose increases 35.…”

Section: Discussionsupporting

confidence: 80%

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial

Azar

Echtay

Bebakar

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimsCompare effects of liraglutide 1.8 mg and sulphonylurea, both combined with metformin, on glycaemic control in patients with type 2 diabetes (T2D) fasting during Ramadan.Materials and methodsIn this up to 33‐week, open‐label, active‐controlled, parallel‐group trial, adults [glycated haemoglobin (HbA1c) 7%‐10% (53‐86 mmol/mol); body mass index ≥20 kg/m2; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once‐daily liraglutide (final dose 1.8 mg) or continue pre‐trial sulphonylurea at maximum tolerated dose, both with metformin. Primary endpoint: change in fructosamine, a validated marker of short‐term glycaemic control, during Ramadan.ResultsSimilar reductions in fructosamine levels were observed for both groups during Ramadan [liraglutide (−12.8 µmol/L); sulphonylurea (−16.4 µmol/L); estimated treatment difference (ETD) 3.51 µmol/L (95% CI: −5.26; 12.28); p = 0.43], despite lower fructosamine levels in the liraglutide group at start of Ramadan. Fewer documented symptomatic hypoglycaemic episodes were reported in liraglutide‐treated (2%, three subjects) versus sulphonylurea‐treated patients (11%, 18 subjects). No severe hypoglycaemic episodes were reported by either group. Body weight decreased more during Ramadan with liraglutide (ETD: −0.54 kg; 95% CI: −0.94;−0.14; p = 0.0091). The proportion of patients reporting adverse events was similar between groups. Liraglutide led to greater HbA1c reduction [ETD: −0.59% (−6.40 mmol/mol), 95% CI: −0.79; −0.38%; −8.63; −4.17 mmol/mol; p < 0.0001].ConclusionsDespite lower fructosamine levels and body weight at the beginning of Ramadan, use of liraglutide showed similar glycaemic improvements, fewer hypoglycaemic episodes and greater body weight reduction compared with sulphonylurea. LIRA‐Ramadan provides evidence for liraglutide being safe and efficacious for management of T2D during Ramadan fasting.

show abstract

Section: Discussionsupporting

confidence: 80%

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial

Azar

Echtay

Bebakar

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…A real-world observational and non-interventional study, VECTOR, conducted in United Kingdom Muslim patients with type 2 diabetes mellitus fasting during Ramadan demonstrated no hypoglycemic events (HEs) and better glycemic control with vildagliptin compared with gliclazide [11] . In a similar study by Devendra et al [12] conducted in North West London, both vildagliptin and gliclazide were associated with similar reductions in mean glycosylated haemoglobin A1c (HbA1c).…”

Section: Introductionmentioning

confidence: 81%

Vildagliptinvssulfonylurea in Indian Muslim diabetes patients fasting during Ramadan

Shete

Shaikh

Nayeem

et al. 2013

WJD

View full text Add to dashboard Cite

AIM:To compare the use of vildagliptin and sulfonylurea with or without metformin in Indian Muslim patients with type 2 diabetes mellitus, fasting during Ramadan. METHODS:This was a 4-wk, multicenter, non-interventional, open-label, observational study. Incidence of hypoglycemic events (HEs), adverse events, and changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose, postprandial plasma glucose and body weight were measured pre-and post-Ramadan. RESULTS:Totally, 97 patients were recruited and all completed the study (vildagliptin group, n = 55; sulfonylurea group, n = 42). HEs were reported in low Key words: Dipeptidyl-peptidase 4 inhibitors; Fasting hypoglycemia; Sulfonylurea; Type 2 diabetes mellitus; Vildagliptin Core tip: Management of glycemic control in diabetes patients fasting during Ramadan has been recognized as a critically important health challenge worldwide. India has the world's second largest diabetes population and caters large Muslim community; however, there is limited data available exploring the effect of treatments

show abstract

“…A number of observational studies have examined the efficacy and safety of DPP-4 inhibitor treatment during Ramadan [32,[43][44][45][46]. In the VECTOR study, no self-reported hypoglycaemic events were reported in the vildagliptin group compared with 35 events in 15 patients (41.7%) in the gliclazide arm (including one severe event).…”

Section: Dipeptidyl Peptidase-4 (Dpp-4) Inhibitorsmentioning

confidence: 99%

Diabetes and Ramadan: Practical guidelines

Hassanein

Alarouj

Hamdy

et al. 2017

Diabetes Research and Clinical Practice

275

357

View full text Add to dashboard Cite

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan

Cited by 75 publications

References 12 publications

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial

Vildagliptinvssulfonylurea in Indian Muslim diabetes patients fasting during Ramadan

Diabetes and Ramadan: Practical guidelines

Contact Info

Product

Resources

About